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Background
The ATP-binding cassette transporter P-glycoprotein
(P-gp) is expressed at the blood-brain barrier (BBB)
where it protects the brain from toxic substances and
xenobiotics by active efflux transport. The
11C-labelled
third-generation P-gp inhibitor [
11C]elacridar was devel-
oped as a positron emission tomography (PET) tracer
for the in vivo quantification of P-gp expression levels in
different organs. The aim of this study was to provide
human dosimetry estimates for [
11C]elacridar based on
whole-body PET.
Methods
Whole-body low dose computed tomography (CT) and
dynamic and static whole-body PET scans were acquired
in 4 healthy subjects for a total of 100 min after i.v.
i n j e c t i o no f4 0 0±8M B qo f[
11C]elacridar using a Sie-
mens Biograph scanner. Volumes of interest were placed
in the brain, liver, pancreas, gallbladder, kidneys, lung,
muscle, heart, spleen, bone marrow and bile by using
ROVER (v. 2.0.31, ABX, Germany) software. Residence
times were derived by spreadsheet calculation and
adapted to the standard human model. Organ doses and
effective dose were calculated utilizing the OLINDA
(v. 1.1, Vanderbilt University) dosimetry program.
Results
Organs with highest radiation burden included pancreas,
spleen, liver and gallbladder wall. Furthermore, lungs,
heart wall and kidneys received above average organ
doses. As excretory organ the gallbladder was identified.
Monoexponential fitting of activity overlying the gall-
bladder suggested that >95% of activity was excreted
via the bile. The calculated effective dose was
7.0×10
−3 mSv/MBq yielding 2.8 mSv for an injected
amount of 400 MBq of [
11C]elacridar.
Conclusions
The estimated radiation burden of [
11C]elacridar is in
the range of other
11C-labeled PET tracers and would
allow multiple PET examinations of the same subject
per year.
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